On September 17, 2019, CV Sciences, Inc. (the “Company”) was informed by the United States Patent and Trademark Office (the “USPTO”) that the Patent Trial and Appeal Board (“PTAB”) had rejected the Company’s appeal to overturn the Examiner’s decision to deny certain claims made within the Company’s patent application (the “Subsequent Notice”), U.S. Patent Application No. 15/426,617 (the “’617 Application”). The Company intends to file a Request for Continued Examination (RCE) of the ‘617 Application, in order to continue to seek and obtain patent protection for the inventions described in the ‘617 Application. The Company believes that at least certain inventions described in the ‘617 Application are entitled to patent protection based on the record that was before the PTAB.

The information set forth in this Current Report on Form 8-K (“Current Report”) contains forward-looking statements. These forward-looking statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Forward-looking statements are based upon assumptions as to future events that may not prove to be accurate. Actual outcomes and results may differ materially from what is expressed in these forward-looking statements.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits

99.1 Press release, dated September 19, 2019

CV Sciences, Inc. Exhibit
EX-99.1 2 pressreleaseseptember192019.htm EXHIBIT 99.1 Exhibit Exhibit 99.1CV SCIENCES,…
To view the full exhibit click here

About CV SCIENCES, INC. (OTCMKTS:CVSI)

CV Sciences, Inc. is a life science company. The Company operates in two segments: specialty pharmaceuticals and consumer products. The Company’s specialty pharma business segment is focused on developing and commercializing therapeutics utilizing synthetic Cannabidiol (CBD) across several therapeutic areas. The consumer product business segment is focused on manufacturing, marketing and selling plant-based CBD products to a range of market sectors.